<p>Sutro Biopharma, Inc. (NASDAQ:STRO - 获取免费报告) 在四月份的空头头寸大幅增加。截至四月十五日，空头头寸总计 748,699 股，比三月三十一日的 639,714 股增加了 17.0%。根据平均每日交易量 260,064 股，目前的覆盖天数比率为 2.9 天。目前，公司 4.7% 的股份被做空。</p>
<p>获取 <strong>Sutro Biopharma</strong> 的提醒：</p>
<h2>Sutro Biopharma 价格表现</h2>
<p>Sutro Biopharma 股票在周四开盘价为 35.39 美元。该公司的 50 日简单移动平均线为 25.39 美元，200 日简单移动平均线为 16.26 美元。Sutro Biopharma 的 52 周低点为 6.74 美元，52 周高点为 36.60 美元。该公司的市值为 5.8634 亿美元，市盈率为-1.36，贝塔值为 1.31。</p>
<h2>分析师评级上调与下调</h2>
<p>几位股票研究分析师最近对该股票发表了评论。Leerink Partners 在 2023 年 4 月 7 日的研究报告中开始覆盖 Sutro Biopharma 的股票。他们给予该公司 “跑赢大盘” 的评级，并设定了 38.00 美元的目标价。Mizuho 在周四的研究报告中为 Sutro Biopharma 设定了 50.00 美元的目标价。德意志银行将 Sutro Biopharma 的目标价从 51.00 美元上调至 55.00 美元，并在 2023 年 3 月 25 日的研究报告中给予该股票 “买入” 评级。HC Wainwright 在 2023 年 3 月 24 日的研究报告中将 Sutro Biopharma 的评级从 “中性” 上调至 “买入”，并将其目标价从 10.00 美元上调至 28.00 美元。最后，Citizens Jmp 在 2023 年 4 月 23 日的研究报告中将 Sutro Biopharma 的目标价从 35.00 美元上调至 41.00 美元，并给予该股票 “市场跑赢大盘” 的评级。一位股票研究分析师给予该股票 “强烈买入” 评级，七位给予 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Sutro Biopharma 目前的平均评级为 “适度买入”，平均目标价为 40.78 美元。</p>
<p><strong>获取我们关于 Sutro Biopharma 的最新研究报告</strong></p>
<h2>机构资金流入与流出</h2>
<p>几家对冲基金和其他机构投资者最近买入和卖出了该公司的股票。田纳西州财政部在第四季度购买了 Sutro Biopharma 的新头寸，价值约 86,000 美元。Jane Street Group LLC 在第四季度购买了 Sutro Biopharma 的新头寸，价值约 265,000 美元。Bridgeway Capital Management LLC 在第三季度将其在 Sutro Biopharma 的股份增加了 232.6%。Bridgeway Capital Management LLC 目前拥有 42,900 股该公司的股票，价值 37,000 美元，此前在上个季度额外购买了 30,000 股。美国银行在第三季度将其在 Sutro Biopharma 的股份增加了 51.3%。美国银行目前拥有 119,434 股该公司的股票，价值 104,000 美元，此前在上个季度额外购买了 40,488 股。最后，Shay Capital LLC 在第三季度将其在 Sutro Biopharma 的股份增加了 20.1%。Shay Capital LLC 目前拥有 312,051 股该公司的股票，价值 271,000 美元，此前在上个季度额外购买了 52,162 股。机构投资者持有该公司 96.99% 的股份。</p>
<h2>关于 Sutro Biopharma</h2>
<p>(获取免费报告)</p>
<p>Sutro Biopharma, Inc 是一家临床阶段的生物制药公司，专注于在肿瘤学和免疫学领域发现和开发新型生物药物候选者。该公司利用其专有的无细胞蛋白合成平台 XpressCF™，设计和生产复杂的多特异性蛋白，包括抗体药物偶联物、双特异性抗体和细胞因子融合蛋白。该平台能够快速生成和优化可能无法通过传统细胞表达系统实现的蛋白治疗。</p>
<p>Sutro Biopharma 成立于 2003 年，总部位于加利福尼亚州南旧金山，已建立了多个处于临床前和临床开发不同阶段的免疫肿瘤候选药物管线。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Sutro Biopharma 更好</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Sutro Biopharma 吗？</h2>
<p>在考虑 Sutro Biopharma 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Sutro Biopharma 并不在名单上。</p>
<p>虽然 Sutro Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

STRO

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

<p>Sutro Biopharma, Inc.（纳斯达克代码：STRO）在四月份的空头头寸增加了 17.0%，截至 4 月 15 日，总计 748,699 股。当前的空头头寸比率为 2.9 天，短售股份占比为 4.7%。该股票开盘价为 35.39 美元，市值为 5.8634 亿美元。分析师给予其 “适度买入” 的平均评级，目标价格为 40.78 美元。机构投资者持有该股票的 96.99%，显示出对该公司的强大机构支持，该公司专注于开发肿瘤学和免疫学领域的生物药物候选者</p>

<p>Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 748,699 shares, an increase of 17.0% from the March 31st total of 639,714 shares. Based on an average daily trading volume, of 260,064 shares, the days-to-cover ratio is currently 2.9 days. Currently, 4.7% of the company's shares are short sold.</p>
<div class="lb-trans"><p>Sutro Biopharma, Inc. (NASDAQ:STRO - 获取免费报告) 在四月份的空头头寸大幅增加。截至四月十五日，空头头寸总计 748,699 股，比三月三十一日的 639,714 股增加了 17.0%。根据平均每日交易量 260,064 股，目前的覆盖天数比率为 2.9 天。目前，公司 4.7% 的股份被做空。</p>
</div><p>Get <strong>Sutro Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sutro Biopharma</strong> 的提醒：</p>
</div><h2>Sutro Biopharma Price Performance</h2>
<div class="lb-trans"><h2>Sutro Biopharma 价格表现</h2>
</div><p>Sutro Biopharma stock opened at $35.39 on Thursday. The company's 50 day simple moving average is $25.39 and its 200 day simple moving average is $16.26. Sutro Biopharma has a fifty-two week low of $6.74 and a fifty-two week high of $36.60. The firm has a market capitalization of $586.34 million, a price-to-earnings ratio of -1.36 and a beta of 1.31.</p>
<div class="lb-trans"><p>Sutro Biopharma 股票在周四开盘价为 35.39 美元。该公司的 50 日简单移动平均线为 25.39 美元，200 日简单移动平均线为 16.26 美元。Sutro Biopharma 的 52 周低点为 6.74 美元，52 周高点为 36.60 美元。该公司的市值为 5.8634 亿美元，市盈率为-1.36，贝塔值为 1.31。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Several equities research analysts have recently commented on the stock. Leerink Partners assumed coverage on shares of Sutro Biopharma in a research report on Tuesday, April 7th. They set an &#34;outperform&#34; rating and a $38.00 price target for the company. Mizuho set a $50.00 price target on shares of Sutro Biopharma in a research report on Thursday. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Sutro Biopharma from $51.00 to $55.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, March 25th. HC Wainwright upgraded shares of Sutro Biopharma from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their price target for the stock from $10.00 to $28.00 in a research report on Tuesday, March 24th. Finally, Citizens Jmp lifted their price target on shares of Sutro Biopharma from $35.00 to $41.00 and gave the stock a &#34;market outperform&#34; rating in a research report on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Sutro Biopharma presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $40.78.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发表了评论。Leerink Partners 在 2023 年 4 月 7 日的研究报告中开始覆盖 Sutro Biopharma 的股票。他们给予该公司 “跑赢大盘” 的评级，并设定了 38.00 美元的目标价。Mizuho 在周四的研究报告中为 Sutro Biopharma 设定了 50.00 美元的目标价。德意志银行将 Sutro Biopharma 的目标价从 51.00 美元上调至 55.00 美元，并在 2023 年 3 月 25 日的研究报告中给予该股票 “买入” 评级。HC Wainwright 在 2023 年 3 月 24 日的研究报告中将 Sutro Biopharma 的评级从 “中性” 上调至 “买入”，并将其目标价从 10.00 美元上调至 28.00 美元。最后，Citizens Jmp 在 2023 年 4 月 23 日的研究报告中将 Sutro Biopharma 的目标价从 35.00 美元上调至 41.00 美元，并给予该股票 “市场跑赢大盘” 的评级。一位股票研究分析师给予该股票 “强烈买入” 评级，七位给予 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Sutro Biopharma 目前的平均评级为 “适度买入”，平均目标价为 40.78 美元。</p>
</div><p><strong>Get Our Latest Research Report on Sutro Biopharma</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Sutro Biopharma 的最新研究报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the company. State of Tennessee Department of Treasury bought a new position in Sutro Biopharma during the 4th quarter worth approximately $86,000. Jane Street Group LLC bought a new position in Sutro Biopharma during the 4th quarter worth approximately $265,000. Bridgeway Capital Management LLC boosted its stake in Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company's stock worth $37,000 after acquiring an additional 30,000 shares during the last quarter. Bank of America Corp DE boosted its stake in Sutro Biopharma by 51.3% during the 3rd quarter. Bank of America Corp DE now owns 119,434 shares of the company's stock worth $104,000 after acquiring an additional 40,488 shares during the last quarter. Finally, Shay Capital LLC lifted its stake in Sutro Biopharma by 20.1% in the third quarter. Shay Capital LLC now owns 312,051 shares of the company's stock valued at $271,000 after buying an additional 52,162 shares in the last quarter. Institutional investors own 96.99% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买入和卖出了该公司的股票。田纳西州财政部在第四季度购买了 Sutro Biopharma 的新头寸，价值约 86,000 美元。Jane Street Group LLC 在第四季度购买了 Sutro Biopharma 的新头寸，价值约 265,000 美元。Bridgeway Capital Management LLC 在第三季度将其在 Sutro Biopharma 的股份增加了 232.6%。Bridgeway Capital Management LLC 目前拥有 42,900 股该公司的股票，价值 37,000 美元，此前在上个季度额外购买了 30,000 股。美国银行在第三季度将其在 Sutro Biopharma 的股份增加了 51.3%。美国银行目前拥有 119,434 股该公司的股票，价值 104,000 美元，此前在上个季度额外购买了 40,488 股。最后，Shay Capital LLC 在第三季度将其在 Sutro Biopharma 的股份增加了 20.1%。Shay Capital LLC 目前拥有 312,051 股该公司的股票，价值 271,000 美元，此前在上个季度额外购买了 52,162 股。机构投资者持有该公司 96.99% 的股份。</p>
</div><h2>About Sutro Biopharma</h2>
<div class="lb-trans"><h2>关于 Sutro Biopharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.</p>
<div class="lb-trans"><p>Sutro Biopharma, Inc 是一家临床阶段的生物制药公司，专注于在肿瘤学和免疫学领域发现和开发新型生物药物候选者。该公司利用其专有的无细胞蛋白合成平台 XpressCF™，设计和生产复杂的多特异性蛋白，包括抗体药物偶联物、双特异性抗体和细胞因子融合蛋白。该平台能够快速生成和优化可能无法通过传统细胞表达系统实现的蛋白治疗。</p>
</div><p>Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>Sutro Biopharma 成立于 2003 年，总部位于加利福尼亚州南旧金山，已建立了多个处于临床前和临床开发不同阶段的免疫肿瘤候选药物管线。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Sutro Biopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Sutro Biopharma 更好</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sutro Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sutro Biopharma 吗？</h2>
</div><p>Before you consider Sutro Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sutro Biopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Sutro Biopharma 并不在名单上。</p>
</div><p>While Sutro Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sutro Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Grows By 17.0%

Market Beat

Sutro Biopharma

瑞穗金融集团

Mizuho Financial Group, Inc.

德意志银行

Citizens Financial

Bridge Investment

美国银行

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Sutro Biopharma 公司（纳斯达克股票代码：STRO）的空头头寸增长了 17.0%